ROLE OF CYTOKINE-MEDIATED MECHANISMS IN DEVELOPMENT OF POST-TRAUMATIC MANDIBULAR OSTEOMYELITIS

Osteomyelitis of the lower jaw is one of the urgent problems of modern medicine. There are many reasons for the evolvement of purulent necrotic processes of the jaw bones, including the role of disorders in the systems of innate and adaptive immunity. The aim of the study was to determine the content of TNFα, IL-17, IL-4 in serum and mixed saliva in patients with uncomplicated mandibular fractures and posttraumatic osteomyelitis to determine the possibility of using these indicators for early diagnosis of posttraumatic complications. The article presents the results of a study of tumor necrosis factor α (TNFα), interleukin-17 (IL-17) and interleukin-4 (IL-4) cytokines in serum and mixed saliva in patients with uncomplicated mandibular fracture and post-traumatic osteomyelitis at the first and tenth days of observation. By means of single-layer neural networks, binary classifiers were built, allowing patients to be stratified by the clinical form of the disease and to predict its course. The probability of uncomplicated mandibular fracture is described by the ratio P = 1/(1+e^-z), where the index z is determined by the level of TNFα, IL-17, and IL-4 at the first and tenth day of observation. The simulation confirmed high prognostic significance of serum TNFα and IL-17 for early verification of posttraumatic osteomyelitis, which was confirmed by the OTC and ROC indices, which varied from 87 to 100% in different models. Models 4 and 5, where TNFα recorded on the tenth day of the study was used as predictors, and a combination of TNFα and IL-17 obtained on the first day of hospitalization, were the most accurate. Modeling the results of the study of immunological indicators in the mixed saliva showed that the predictive properties have only IL-4 and IL-17, was on the tenth day of hospitalization that distinguishes these binary classifiers from similar indexes, derive from the levels of cytokines in blood serum. The results of the study indicate the important role of disorders in the system of рro- and anti-inflammatory cytokines in pathogenesis of post-traumatic osteomyelitis.

1. Kirpichnikov M.V., Podolsky V.V. On the issue of etiological factors of traumatic osteomyelitis of the mandible. Aktualnye voprosy stomatologii = Topical Issues of Dentistry, 2017, рр. 172-176. (In Russ.)

2. Kuligin D.A. Etiological factors of traumatic osteomyelitis. Byulleten meditsinskikh Internet-konferentsiy = Bulletin of Medical Internet Conferences, 2017, Vol. 7, no. 10, pp. 1536-1537. (In Russ.)

3. Malyutina A.V., Nikolaeva B.V., Pinelis I.S., Turchina E.V. Cause-and-effect relations of development of traumatic osteomyelitis of jaws. Meditsina zavtrashnego dnya = Medicine of Tomorrow, 2017, рр. 137-138. (In Russ.)

4. Matchin A.A., Abdullayev M.D., Akhmerova R.I., Rakhmatullin T.R. Clinical analysis of immunological risk factors for the development of inflammatory-destructive process in the bones of the facial skeleton. Sovremennye meditsinskie issledovaniya = Modern Medical Research, 2018, pp. 27-29. (In Russ.)

5. Sivukhina  O.V., Goryaynova K.V. Assessment of risk factors in the development of traumatic osteomyelitis in the treatment of mandible fractures. Gigiena: zdorovye i profilaktika = Hygiene: Health and Prevention, 2018, pp. 194-195. (In Russ.)

6. Simbirtsev A.S. Cytokines in the pathogenesis and treatment of human diseases. St. Petersburg: Foliant, 2018. 512 p.

7. Delsing C.E. Th17 cytokine deficiency in patients with Aspergillus skull base osteomyelitis. BMC Infect. Dis., 2015, Vol. 15, p. 140.

8. Kim S.M., Eo M.Y., Cho Y.J. Immunoprecipitation high performance liquid chromatographic analysis of healing process in chronic suppurative osteomyelitis of the jaw. J. Craniomaxillofac. Surg., 2018, Vol. 46, no. 1, pp. 119-127.

9. Kharazmi M., Hallberg P. Mucosal trauma and osteonecrosis. Am. J. Orthod. Dentofacial Orthop., 2018, Vol. 154, no. 2, p. 155.

10. Morita M. Elevation of pro-inflammatory cytokine levels following antiresorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis. Sci. Rep., 2017, Vol. 7, 46322. doi: 10.1038/srep46322.